These results show that CD5 is a better target than CD3 for T-cell lymphomas and that a NK-specific CAR framework, when expressed in NK effector cells, is more efficient to target tumors in vivo in correlation with its increased cytotoxic activity. This evidence concerns the gene CD5 and T-cell non-Hodgkin lymphoma.